Skip to main content
. Author manuscript; available in PMC: 2021 Jun 12.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Oct 4;25(2):369–381. doi: 10.1016/j.bbmt.2018.09.038

Figure 2.

Figure 2.

Time to clinically significant CMV infection (A) and time to all-cause mortality (B) from day of transplantation through week 24 post-transplantation, intention-to-treat population. Patients without a clinically significant CMV infection were censored at the end-of-study visit or at 24 weeks (+2-week window) after transplantation, whichever was earlier. For mortality through week 24, patients who died after week 24 post-transplantation were censored at the end-of-study visit or week 24, whichever was earlier.